Nohla Therapeutics

1616 Eastlake Avenue East
Suite 202
Seattle
Washington
98102
United States

Tel: 206-519-5300

About Nohla Therapeutics

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Michael Sistenich
CMO: Dr. Colleen Delaney
CFO: Darren Scotti
Vice President, Manufacturing: Jason Carstens
Director of Program Management: Heather Brammer
JOBS:
Please click here for Nohla's job opportunities.
SCIENCE:
Please click here for Nohla's science.

10 articles about Nohla Therapeutics

Nohla Therapeutics Receives FDA Orphan Drug Designation for Dilanubicel for Hematopoietic Stem Cell Transplant Patients

7/16/2018

Nohla Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Nohla’s lead product candidate, dilanubicel (NLA101), Orphan Drug Designation for reduction of morbidity and mortality associated with hematopoietic stem cell transplant (HSCT).
Nohla Therapeutics Announces Second Closing of $56 Million Series B FinancingAdditional $11 Million Raised from Three New International Investors and One Existing Investor

7/11/2018

Nohla Therapeutics announced the second closing of its Series B financing, bringing the total amount raised in this round to $56 million.
Nohla Therapeutics Selects Advanced Therapies Business Unit of WuXi AppTec to Manufacture Universal Donor Cell Therapies

3/21/2018

“We are excited to partner with WuXi AppTec Advanced Therapies to gain their expertise and cGMP manufacturing capabilities to support the ongoing development and anticipated global commercial demand for our lead cell therapy program, NLA101,” said Katie Fanning, President and Chief Executive Officer of Nohla.
Nohla Therapeutics Initiates Global LAUNCH Phase II Trial of NLA101 in Patients With AML

2/14/2018

The trial will evaluate Nohla’s lead product candidate, NLA101, in adult patients with AML who are at risk for myelosuppression after receiving high-dose chemotherapy.
Nohla Therapeutics Granted Orphan Drug Designation in the European Union for NLA101 in the Treatment of Hematopoietic Stem Cell Transplantation

1/23/2018

The primary endpoint of the Phase 2b study is time to engraftment with an absolute neutrophil count (ANC) ≥ 500.
Nohla Therapeutics Announces Hiring of Jim Johnson as Chief Financial Officer

1/5/2018

Mr. Johnson joins Nohla after serving for five years as the CFO of NanoString Technologies.
CryoPort To Provide Nohla Therapeutics With Cutting Edge Cold Chain Logistics To Support Clinical Programs

10/2/2017
Nohla Therapeutics Awarded $6.9 Million Grant From The California Institute Of Regenerative Medicine To Further Develop NLA101 Cell Therapy For The Treatment Of Patients With Acute Myeloid Leukemia

9/29/2017
Seattle-Based Biotech Nohla Therapeutics Nabs $43.5 Million to Develop Universal Donor Cellular Therapies

11/30/2016
Nohla Therapeutics Signs Exclusive Supply Agreement With LifeSouth Community Blood Centers

10/19/2016